BioSante Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology / Healthcare / Pharmaceuticals Investor Forum
August 22, 2005
Webcast Alert: BioSante Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology / Healthcare / Pharmaceuticals Investor Forum to be Webcast on Thursday, August 25, 2005, 10:00 am ETLINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Aug. 22, 2005--BioSante Pharmaceuticals, Inc. (AMEX: BPA) will present at the following forum:
What: BioSante Pharmaceuticals, Inc. (AMEX: BPA) will give a presentation at Informed Investors Biotechnology / Healthcare / Pharmaceuticals On-line Investors Forum.
The keynote presentation will be from Dr. Adam K. Noah, Research Analyst with Granite Financial Group
When: August 25, 2005 @10:00 AM Eastern Time
Where: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493
How: Live over the Internet--Simply log on to the web at the address above.
Contact: Phillip Donenberg, Chief Financial Officer, donenber@biosantepharma.com , (847)478-0500
If you are unable to attend the live event, the forum will be archived and available via the Informed Investors website at http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.